about
Human immunodeficiency virus type 1 gp120 and other activation stimuli are highly effective in triggering alpha interferon and CC chemokine production in circulating plasmacytoid but not myeloid dendritic cells.Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel diseaseVitamin D receptor agonists, cancer and the immune system: an intricate relationshipDendritic cells as key targets for immunomodulation by Vitamin D receptor ligands.A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development.Manipulating dendritic cells to induce regulatory T cells.Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3.1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells.Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells.Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases.Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivoPharmacological induction of tolerogenic dendritic cells and regulatory T cells.BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity.A gut-vascular barrier controls the systemic dissemination of bacteria.Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin.Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells.Control of autoimmune diseases by the vitamin D endocrine system.Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis.Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3.Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation.Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis.Thiol antioxidants inhibit the formation of the interleukin-12 heterodimer: a novel mechanism for the inhibition of IL-12 production.Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol.Polymorphisms in the Il12b gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains.Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.Induction of transplantation tolerance by 1,25-dihydroxyvitamin D(3).Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D(3).Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists.The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model.Calcitriol derivatives with two different side chains at C-20 III. An epimeric pair of the gemini family with unprecedented antiproliferative effects on tumor cells and renin mRNA expression inhibition.Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol)Early Th1 response in unprimed nonobese diabetic mice to the tyrosine phosphatase-like insulinoma-associated protein 2, an autoantigen in type 1 diabetesFunctional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cellsDeviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetesCutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells
P50
Q24533328-453B68A0-F593-4602-A094-B87FCC7AC54FQ28116241-24BFB4BD-D4D1-479B-AF71-FDA7FADB6230Q28252751-3F55668A-3930-430D-BB7B-596AC7976D39Q33204344-D0D97BA0-8208-482E-8A45-69452E78DD42Q33205503-2C836A76-FD06-42A6-9BFD-D0EFA3FCF884Q33215907-A064CC3F-A064-40C3-9DD3-F7EE0FA409CBQ33219961-CB616C26-95EB-4A0A-960B-95BD41F63D36Q33267228-EA2BA891-B9B7-424B-9980-48103921E3B6Q34556765-24E84BA0-FA83-4EC9-BFAA-2A6B3890E596Q35024786-D99DAFAC-0D19-4B3F-9F55-D0D1FB2D48FDQ35042170-9CEBE59D-64CC-4190-8050-D9437D48B7D9Q35092636-AB796310-8E94-493A-973A-1FA5943EF74DQ35703546-5BA0C244-A374-4FDB-BE83-42AEE1D90C9AQ35771298-1A1CC44D-AFF0-4DC9-A4AE-F3CD1A1FF7E7Q35840463-598AB1F8-D039-4A9B-9D76-CAFF5599DDFFQ35947790-349DB207-E566-4B17-BF6F-329C3489510CQ37091003-7E43FBE3-49AF-45CB-A5C5-5A95C98A37D2Q37204961-A90C1B1A-EB89-4E7C-B7A6-78FBF68DE92CQ37512391-329AFDFE-4B3B-441F-B445-5C61C9B04C95Q37732379-A5818A1A-93CA-4B93-8E80-AAC93D7753BBQ38773904-78086BD4-2E53-4E37-B763-93AE3089E5C1Q39307644-4E728478-E685-40FC-80D3-8B12112B76FEQ39869035-9F21A2C7-4D0D-453C-9577-D5D083E8482AQ39870686-FECD79B2-058B-4CDE-9975-51FEE8672E1CQ40704608-F30B5762-533D-4D84-BCB8-EC89C30B35FCQ40725737-0E5CC1FE-191D-4242-8211-1A348CD03F96Q42505016-44630A45-9A45-490A-8E8E-327D2618BA8CQ42522530-EE7C8347-4ECB-4855-8EB6-71088D2CB1CDQ43115722-5CBC02A5-3EB3-4DE4-BCBE-E741745CBEF3Q43552515-7BBBEA10-0800-4AC6-8E8C-08F404A9937BQ43620657-166C4CD2-D32B-49BE-B05B-6EB00600BA54Q46030799-FB372647-5678-421E-9678-9FD50D09B00EQ46183765-D6F39B2C-245D-424B-9BBE-C6FFF92E9C5FQ47245367-4587028E-9FB1-4656-AE5B-391CF234BBCFQ53337552-9047BF11-A6A5-4A88-B708-71CC0EC41874Q61971021-2D385D51-F4C3-447E-8704-4171903C31C4Q73306750-FB2A9430-86D6-43CD-90E9-0A1EEE4D4AADQ73406951-003CC30E-DAF1-4CC4-9B88-FFF624E9B8E9Q73814889-8D770FB8-25D0-4816-8BA8-FA1E253E886BQ74321391-C4811500-766C-48B4-BFC7-D24AC362A257
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Penna
@ast
Giuseppe Penna
@en
Giuseppe Penna
@es
Giuseppe Penna
@nl
Giuseppe Penna
@sl
type
label
Giuseppe Penna
@ast
Giuseppe Penna
@en
Giuseppe Penna
@es
Giuseppe Penna
@nl
Giuseppe Penna
@sl
prefLabel
Giuseppe Penna
@ast
Giuseppe Penna
@en
Giuseppe Penna
@es
Giuseppe Penna
@nl
Giuseppe Penna
@sl
P106
P1153
7004643293
P21
P31
P496
0000-0003-3534-7090